Gala vs Hims: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

49 providers verified independently·Independent research·How we rank →

Hims beats Gala overall, scoring 7.9/10 vs 7.2/10. Gala is more affordable at $149/mo vs $199/mo. Choose Gala for tirzepatide-first patients who want a low-cost compounded pa. Choose Hims for men who want a well-known publicly-traded brand and fda-appr.

A side-by-side comparison of Gala and Hims covering pricing, scores, medication types, insurance, and more to help you decide.

Gala

#40 of 49

7.2/10

Telehealth platform focused on compounded tirzepatide — both microdose and full-dose tiers — alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.

Visit Gala

Higher Rated

Hims

#12 of 49

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership — alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026) — significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28% — the highest 1-star rate in our table — clustered around subscription/billing complaints.

Visit Hims

Feature	Gala	Hims
Our Score	7.2/10	7.9/10
Starting Price	$149/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated iOS + Android tracker app for daily progress logging	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership — but should know going in that Hims' customer-experience signal is weaker than smaller competitors
Ranking	#40	#12

Pros & Cons Compared

Gala

Pros

+Microdose compounded tirzepatide at $149/mo — the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
+Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android — first-party in-treatment logging is uncommon among compounded-only platforms
+OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
+All 50 states, free shipping, no insurance required, 24/7 patient support claimed

Cons

−Brand-name Ozempic pricing ($1,299/mo) is materially above market — NovoCare direct pricing for Wegovy is $349/mo, Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership
−Tirzepatide-only on the compounded side — compounded semaglutide is NOT offered, narrower medication menu than peers like Maximus, Ro, or Henry Meds
−Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness — verify your specific dose and batch with each refill
−Initial consultation typically a sync video visit, but ongoing follow-ups and questions are chat-based (no scheduled ongoing video access) — and no published labs, no named medical director, no specialty obesity oversight
−Restrictive refund policy — Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
−Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn) — limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself

Hims

Pros

+Publicly traded company (NYSE: HIMS) — SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership — FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
+Polished app and web experience — among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461) — significant real-world adoption.

Cons

−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026) — significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star — the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss) — not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1 — it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
−Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
−Generic high-volume support — large patient base means less personalized attention than smaller competitors.

Our Verdict

Hims edges out Gala with a score of 7.9/10 vs 7.2/10. If budget is your priority, Gala starts at $149/mo compared to Hims's $199/mo. Choose Gala if you want: tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership — but should know going in that hims' customer-experience signal is weaker than smaller competitors.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Gala nor Hims feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review